MEDIPOST
MEDIPOST Raises $140M | Regenerative Medicine for Osteoarthritis
MEDIPOST Closes $140M for Stem Cell Therapy
MEDIPOST, a regenerative medicine company, has raised $140 million in late-stage private funding to advance its allogeneic stem cell therapy for knee osteoarthritis treatment.
The round was led by Skylake Equity Partners and Crescendo Equity Partners.
Key Highlights
- Focus on knee osteoarthritis treatment
- Allogeneic stem cell therapy platform
- Korean growth investor backing
Company Overview
MEDIPOST is developing regenerative medicine therapies using allogeneic stem cells, with a lead program targeting knee osteoarthritis to provide patients with alternatives to joint replacement surgery.
Company Info
Investors (2)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


